Table 4.

Between-group comparison of liraglutide pharmacokinetics. Ratios and 90% CI comparing hepatically impaired groups to the healthy subject group

	Hepatic impairment group
	Mild/healthy	Moderate/healthy	Severe/healthy
AUC (0,∞) Estimate (90% CI)	0.77 (0.53, 1.11)	0.87 (0.60, 1.25)	0.56 (0.39, 0.81)
Cmax Estimate (90% CI)	0.89 (0.65, 1.21)	0.80 (0.59, 1.09)	0.71 (0.52, 0.97)
t1/2 (h) Estimate (90% CI)	0.95 (0.83, 1.10)	1.01 (0.88, 1.17)	0.85 (0.73, 0.98)
CL/F Estimate (90% CI)	1.30 (0.90, 1.87)	1.15 (0.80, 1.66)	1.78 (1.23, 2.58)
Vz/F Estimate (90% CI)	1.23 (0.86, 1.77)	1.17 (0.82, 1.67)	1.51 (1.05, 2.17)

AUC(0,∞), area under the liraglutide plasma concentration–time curve from time zero to infinity. The measurements were performed up to 72 h after liraglutide dosing. C_max, maximum liraglutide plasma concentration. t_max, time to reach maximum liraglutide concentration. t_1/2, terminal plasma half-life calculated as t_1/2 = ln2/λ_z. λ_z, terminal elimination rate constant, calculated by log-linear regression on the log linear phase of the plasma concentration profile. CL/F, total apparent clearance, estimated as CL/F = dose/AUC. V_z/F, apparent volume of distribution, estimated as V_z/F = (CL/F)/λ_z.